2024 annual financial data
Lyell Immunopharma 2024 Net margin
Direct answer
Net margin was -562,285.25%.
Operating income was -358.76M USD and net income was -342.99M USD.
Operating cash flow was -162.39M USD.
Get free Lyell Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 61,000 USD
- Operating income
- -358.76M USD
- Net income
- -342.99M USD
- Operating cash flow
- -162.39M USD